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A Correlation between Protein Function and Ligand Binding
Profiles
Matthew D. Shortridge, Michael Bokemper, Jennifer C. Copeland, Jaime L. Stark, and
Robert Powers*
Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588-0304
Abstract
We report that proteins with the same function bind the same set of small molecules from a
standardized chemical library. This observation led to a quantifiable and rapidly adaptable method
for protein functional analysis using experimentally-derived ligand binding profiles. Ligand
binding is measured using a high-throughput NMR ligand affinity screen with a structurally
diverse chemical library. The method was demonstrated using a set of 19 proteins with a range of
functions. A statistically significant similarity in ligand binding profiles was only observed
between the two functionally identical albumins and between the five functionally similar
amylases. This new approach is independent of sequence, structure or evolutionary information,
and therefore, extends our ability to analyze and functionally annotate novel genes.
Keywords
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INTRODUCTION
The recent explosion in sequenced genomes has revealed a vast number of proteins that lack
a functional annotation.1 Many of these unannotated proteins may play an important role in
human disease and, correspondingly, are critical for developing new therapeutics. Protein
sequence and structure similarity methods are currently the most robust and widely-used
tools to annotate a protein of unknown function.2 Nevertheless, these methods are limited in
scope, prone to errors, and based on a small set of experimentally characterized proteins.3
Only 40 to 60% of sequences suggest a potential functional assignment. Moreover, error
rates of < 30% occur even with conservative sequence identities of > 60%. The accuracy of
functional annotations decreases substantially in the twilight zone of 20–35% sequence
identity.
Recent attempts to extend functional prediction beyond global sequence and structure
similarity have led to the development of active-site similarity search methods.4–7 These
methods try to identify protein surface structures that interact with biologically important
ligands since active-sites that share a similarity in sequence, structure and ligand binding are
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predicted to be functionally related. This is based on the fundamental principal that a
protein’s active-site has been optimized by nature to interact with a unique and specific set
of targets, where this information can be leveraged to understand function. Consequently,
protein surfaces have been shown to be exquisitely selective and to only bind ligands at very
specific functionally relevant locations.8–11 This understanding is also essential to drug
discovery, where extensive resources are allocated by the pharmaceutical industry to
identify high-affinity and selective compounds that target a specific therapeutically relevant
protein.12, 13 The use of ligands as functional probes is the basis of our FAST-NMR
methodology4, 14 that has been sucessfuly applied to explore the function of Staphylococcus
aureus protein SAV1430,4 Pseudomonas aeruginosa protein PA1324,15 Pyrococcus
horikoshii OT3 protein PH1320,14 human protein Q13206,14 Bacillus subtilis protein
YndB,16 and Salmonella typhimurium PrgI protein.17 Similar successes have been reported
using ligand binding to infer function in virtual screens.18, 19 While promising, current
active-site similarity techniques still rely on high-resolution protein structures to identify and
measure functional similarity.20 The availability of structures for the entire proteome
remains a significant bottleneck for the high-throughput functional annotation of
hypothetical proteins.
We report herein a new method to infer protein function that is independent of sequence and
structural information. Our method uses a similarity in ligand binding profiles to annotate a
protein of unknown function. This is similar in concept to the mapping of pharmacological
space or the use of structure-activity relationships (SAR) for target selection and chemical
lead identification in drug discovery.21–24 A ligand binding profile is defined as a set of
ligands that bind a protein from a high-throughput ligand affinity screen. Ligand binding is
monitored using our 1D 1H NMR line-broadening screen.25 In essence, the chemical and
structural diversity of a compound library provides an experimental means of mapping the
physiochemical properties of a protein’s active-site based on the compounds that do or do
not bind the protein. Functional annotation is inferred by clustering unknown proteins with
previously annotated proteins that share similar ligand binding profiles from the same
chemical library. A modification of the E-value routinely used in sequence homology is
used to quantify ligand binding profile similarities. The methodology is demonstrated using
19 proteins with a range of function defined by Gene Ontology (GO) terms.26
EXPERIMENTAL
Materials
The human serum albumin (HSA) (essentially fatty acid free, ≥ 96 % pure), bovine serum
albumin (BSA) (minimum 98% agarose gel electrophoresis, lyophilized), α-amylase from
Bacillus lincheniformis (Bli) (500–1,500 units/mg protein, 93–100% (SDS page)), α-
amylase from Aspergillus oryzae (Aor) (powder, ~30 units/mg), α-amylase from Bacillus
amyloliquefaciens (Bam) (liquid, ≥250 units/g protein), β-amylase from barley (Hvu) (type
II-B 20–80 units/mg protein), and β-amylase from sweet potato (Iba) (Type I-B, ammonium
sulfate suspension, ≥750 units/mg protein) protein samples were all purchased from Sigma
(St. Louis, MO). The S. typhimurium PrgI protein samples and assigned 1H-15N HSQC
spectrum were generously provided by Dr. Roberto DeGuzman (University of Kansas).
Staphylococcus aureus primase C-Terminal domain (CTD) protein sample was purchased
from Nature Technologies Corporation (Lincoln, NE). H. sapiens diacylglycerol kinase
alpha (DGKA), P. aeruginosa unannotated protein PA1324, S. aureus unannotated protein
SAV1430, S. typhimurium unannotated protein STM1790, H. sapiens ubiquitin-fold
modifier-conjugating enzyme 1 (UFC1), E. coli unannotated protein YjbR, E. coli
unannotated protein YkfF, B. subtilis unannotated protein YkvR and E. coli unannotated
protein YtfP protein samples were provided by Dr. Gaetano Montelione, Director of the
Northeast Structural Genomics Consortium (NESG, www.nesg.org). The S. aureus nuclease
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was over-expressed in house from a cell stock of E. coli Bl21 DE3 codon+ (Stratagene)
containing the pET28(a)+plasmid with the dnuc gene provided by Dr. Greg Somerville
(University of Nebraska-Lincoln) grown in LB broth and purified using a Talon cobalt
affinity resin (Clontech). The deuterium oxide (99.9 atom% D) and the dimethyl sulfoxide-
d6 (99.9% D) were purchased from Aldrich (Milwaukee, WI) The 3-
(trimethylsilyl)propionic acid-2,2,3,3-d4 (TMSP-d4) was purchased from Cambridge Isotope
(Andover, MA). The Bis-Tris-d19 (98 atom% D CP) was purchased from Isotec
(Milwaukee, WI). The compound library was previously complied as described elsewhere.27
NMR Data Collection and Sample Preparation
All NMR data was collected on a Bruker 500 MHz Avance spectrometer (Billerica, MA)
equipped with a triple resonance, Z-axis gradient cryoprobe and using a Bruker BACS-120
sample changer and IconNMR software for automated data collection. The screening data
for this study was compiled over a 5 year time span in which two different 1D 1H solvent
suppression pulse sequences were used for the measurement of ligand 1D 1H NMR line
broadening. Data for the HSA, BSA, S. aureus primase CTD, PrgI, PA1324, and SAV1430
were collected as previously described.4, 15, 17, 25 Data for DGKA, STM1790, UFC1, YjbR,
YkfF, YkvR and YtfP, the 5 amylases and S. aureus nuclease proteins was collected at 298
K using 64 transients with a spectrum width of 6009 Hz with 8 K data points and a 1.0 sec
relaxation delay using the excitation sculpting28 method for solvent suppression of the
residual H2O resonance signal. The samples for the HSA, BSA, S. aureus primase CTD,
PrgI, PA1324, and SAV1430 NMR screens were prepared as previously described.4, 15, 17 S.
aureus nuclease, DGKA, STM1790, UFC1, YjbR, YkfF, YkvR, YtfP, and the 5 amylases
were screened at 5 μM protein concentration and 100 μM ligand concentration in a
screening buffer of 2% DMSO-d6, 20 mM Bis-Tris pH 7.0, 11.1 mM TMSP-d4 in “100%”
D2O.
Chemical Library
All NMR ligand affinity assays were completed by screening each protein individually with
a library of 437 biologically active compounds (http://bionmr-c1.unl.edu/ligands).27 The
library contains amino-acids, carbohydrates, co-factors, fatty-acids, hormones, inhibitors,
known drugs, metabolites, neurotransmitters, nucleotides, and substrates. The compound
library is divided into 116 mixtures with 3–4 ligands per mixture and is described in detail
elsewhere. In order to assess the structural diversity of the library, 1300 molecular
descriptors were calculated for each compound using the online software eDragon
(VCClabs, http://www.vcclab.org/lab/edragon/).29 MM2 minimized 3D MOL2 files were
generated using ChemBio 3D Ultra 12.0 (CambridgeSoft, Cambridge, MA), converted to
SMILES using OpenBabel (http://openbabel.org) and then uploaded to the eDragon web
site. The molecular descriptors calculated for each structure were incorporated into a single
Excel spreadsheet and imported into SIMCA (UMETRICS, Kinnelon, NJ). Each molecular
descriptor was treated as separate bin or data point for each structure. A 3D PCA scores plot
was generated using the calculated molecular descriptors for the structures in the library.
False positive and false negative rates were simulated to determine if the screening library of
437 compounds is of sufficient size to make meaningful comparisons between proteins of
unknown function. An in-house program was written that randomly generates a ligand
binding profile using a Gaussian distribution about two means: (i) average hit rate of 32 ± 44
bound ligands, or (ii) a lower hit rate of 16 ± 6. Either 1×106 random pairs of ligand binding
profiles were generated or a single randomly generated ligand binding profile was compared
against a random set of 1×106 ligand binding profiles. The simulations were done in
triplicate and the library sizes used in the simulations corresponded to 437, 1,000, 2,000,
5,000, and 10,000 compounds. An E-value of ≤ 1×10−9 was used to define a similar ligand
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binding profile. A histogram of the Log(E-values) were plotted and fitted using EasyFit
V5.4 (MathWave Technologies).
To estimate a false negative rate, an error was introduced to randomly generated pairs of
identical ligand binding profiles. Each ligand binding profile has false binders added or true
binders removed at a percentage of the rate that a true binder was added to the original
ligand binding profile (based on the original number of predicted binders (m and n) chosen
from the Gaussian distribution):
(1)
where e is the error rate (10%-50%), me and ne (me ≠ ne) are the new number of bound
ligands after the error rate is applied, and mo and no (mo = no) are the original number of
bound ligands predicted from the Gaussian distribution.
Binding Assay
Ligand binding was manually identified from a decrease in the free ligand 1D 1H NMR
signal upon the addition of protein. This decrease is determined by visually comparing
ligand peak intensities to the TMSP-d4 methyl resonance (0.00 ppm) from the 100 μM
TMSP-d4 internal standard. Any ligand with a visually observable decrease in peak height
from the addition of a protein is considered to be a binder. A detailed analysis of the
relationship between KD and NMR line-broadening has been previously discussed in
detail.30 From this analysis, a conservative estimate of our limit of detection can be made,
which corresponds to ligands with a KD of > 100–300 μM. Of course, this limit is dependent
on the molecular-weight of the protein, where sensitivity increases with MW. Thus, our
ligand binding assay will be dominated by biologically relevant protein-ligand interactions,
where non-specific or irrelevant interactions start to dominate as the KD increases beyond
300 μM.31 Conversely, tight-binders (KD ≤ nM) that are governed by slow-off rates may
simply result in a decrease in peak intensity proportional to the limiting protein
concentration. A 5% change in peak intensity may be difficult to decipher and correspond to
a false positive. Nevertheless, encountering tight binders in ligand binding assay is generally
a rare event. Binders from our chemical library are typically structural homologs to the
natural ligand. Also, these tight binders would be expected to be uniformly missed for
functionally similar proteins. The methods for data processing and identifying binding
ligands have been previously discussed in detail.25, 27, 30 Overall, for our library of 437
compounds, the 1D 1H NMR line-broadening screen requires approximately a day to
complete both the data acquisition and the data analysis.
Ligand Binding Profiles
A similarity in ligand binding profiles was measured between each pair of proteins using
equation 1. Overlapping binding ligands (S) for every protein in a pairwise manner were
identified by comparing a list of all binding ligands and counting the number of overlapping
ligands. Each pairwise E-value was calculated using a library size of 437 compounds (p =
1/437 = 0.00229). An Excel spreadsheet program was written to match overlapping ligands
and measure E-values.
Functional Similarity Measurement
The Uniprot accession number was obtained for each protein in the study. The list of
Uniprot accession numbers was uploaded to the semantic similarity tool FunSimMat
(http://funsimmat.bioinf.mpi-inf.mpg.de/). All reported functional similarities are expressed
as a funsim score measured as previously described.32
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RESULTS AND DISCUSSION
Structural Diversity of the Screening Library
Our chemical library for NMR ligand affinity screening was designed to maximize
functional diversity.27 In addition to practical considerations such as solubility, stability and
cost, compounds were added to our library based on a known biological activity involving a
distinct protein or protein class. Compounds correspond to known drugs, inhibitors,
substrates or cofactors. Not surprisingly, the compounds are also consistent with typical
“drug-like” characteristics and with fragment libraries.33, 34 These characteristics include
good aqueous solubility, low molecular-weights, and low number of rings, heteroatoms, and
hydrogen-bond donors and acceptors. Diversity in biological activity was also anticipated to
result in a correlated diversity in chemical structure. To validate the structural diversity of
our functional chemical library, ~1,300 different molecular descriptors were calculated for
each compound.29 A principal component analysis (PCA) of the set of molecular descriptors
indicates a uniform coverage of structural space. A 3D PCA scores plot is shown in Figure
1A. The structures are distributed throughout the structural space defined by the molecular
descriptors. Conversely, if there was an overabundance of any structural class, distinct
clustering patterns would be apparent in the 3D PCA scores plot. Clearly, our chemical
library is an acceptable set of molecular probes to evaluate a diversity of protein function.
Calculation of Ligand Binding Profile Similarities
Measuring a significant similarity between two ligand binding profiles requires the
development or adaptation of a robust scoring function. Current similarity scoring methods
used for sequence analysis, such as the E-value developed by Karlin and Altschul,35 are also
well-suited for measuring a similarity between ligand binding profiles.
(2)
Here, the E-value is only dependent on the total number of compounds that bind each
protein (m and n) and the total number of compounds that bind both proteins (S).
Additionally, the probability of finding a significant similarity is proportional to the
probability search space (K) and scoring function (λ).
(3)
Unlike sequence similarity, a similarity between ligand binding can be thought of as a binary
system (binding vs. non-binding) therefore the probabilities p′ and q simply becomes the
probability of finding a hit within a library:
(4)
and the probability of finding a ligand that binds both proteins:
(5)
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The standard E-value also provides a robust measure of the probability that the ligand
binding similarity is not due to chance using the standard P-value.
(6)
As expected, the ligand binding profile E-value rapidly becomes insignificant (P > 0.0001)
as the probability of finding a ligand that binds both proteins (q) decreases. Binding profiles
that have a P < 0.0001 are significant at the 99.99% confidence interval (E=10−5). Thus, our
method is only dependent on comparing the total number of binding events (m or n) and the
set of overlapping binding ligands (S) between two proteins.
Sufficient Size of a Screening Library
Obtaining a balance between library depth and breadth is very challenging and has been a
focus of compound library design for over a decade – without a clear consensus
conclusion.36 Clearly, the size of the library would be expected to impact the number of
observed binders (m and n) and the corresponding similarity in ligand binding profiles (S
and E-value). Fundamentally, determining the optimal size of the chemical library is an
open-ended, and at some level, a very difficult question to adequately answer. It is always
plausible for a protein to be screened that results in a complete absence of binders regardless
of the size or composition of the chemical library. If the protein is a true unknown, how is it
possible to ascertain a priori that the library composition is adequate? The only recourse is
to explore the probability of identifying binders within a given set of reasonable assumptions
and given experimental hit rates.
On average, 32 ± 44 ligands were observed to bind a protein target in our NMR ligand
affinity screen. Our simulations indicate that even with a modest library size of 437
compounds, the probability of randomly finding two similar (E-value ≤ 1×10−9) ligand
binding profiles was shown to be effectively zero. This is not too surprising considering that
in theory there are 2437 (3.5×10131) different binding profiles, where the product (1.3×10263)
leads to an effectively miniscule probability of finding two similar ligand binding profiles.
Of course, only a small subset of these potential ligand binding profiles are possible given
32 ± 44 bound ligands, but this still represents a very large number of dissimilar pairs of
ligand binding profiles. A randomly selected ligand binding profile using a Gaussian
distribution of bound ligands with a smaller mean (larger potential false positive rate) of 16
± 6 was compared against a random set of 1×106 ligand binding profiles using the same
Gaussian distribution to select binders. A histogram of the Log(E-values) is shown in Figure
1B and best fitted with the Weibull Distribution (Extreme Value Type III Distribution),
which indicates the calculated E-values are significant.37 Consequently, the comparison did
not yield any significant similarities and the most common occurrence was an overlap (S) of
zero (S ranged from 0 to 7).
While the false positive rate is effectively zero, a false negative rate was measurable and, as
expected, decreased for increasing library size. Again, a total of 1×106 pairs of identical
ligand binding profiles (m=n=S) was randomly generated using a Gaussian distribution with
a mean of 16 ± 6 bound ligands (m and n). An error rate ranging from 10%–50% was
introduced into each ligand binding profile, independently changing the two identical ligand
binding profiles. The simulations were repeated for library sizes that ranged from 437 to
10,000 compounds. The percentage of false negatives (E-value of > 1×10−9) found in each
simulation are plotted as a function of library size in Figure 1C. The false negative rate
increases proportional to the error rate and decreases proportional to the library size. For our
library of 437 compounds, the percentage of false negatives is ~9% with a 50% error rate
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(see eqn. 1). Conversely, only a ~2% false negative rate is observed for a library of 2,000
compounds at the maximum error rate of 50%. The false negative rate is below 1% for a
library of 10,000 compounds. Correspondingly, ligand-binding profile similarities are
relatively tolerant to erroneous binders. This is consistent with the lack of any false
negatives in the 19 screens reported herein. Thus, the simulations indicate that even a
modest library of 437 compounds provides a relatively robust and reliable measure of
functional similarity, but a slight increase in the library size may improve the methods
accuracy. Of course, increasing the library size also increases assay time, but a library of
1500–2000 compounds is still practical since the assay time is only estimated to increase to
~1.5–2 days.
The library size also defines the minimal number of binders (m, n) and overlapping binders
(S) required for obtaining a significant E-value of 1×10−9. For a modest library of 437
compounds, the minimal number of binders and overlapping binders is 5 compounds. The
number drops to 4 compounds for a library size of 1000–2000 compounds and to 2
compounds for a library size of 5000–10000. Considering the average number of binders is
32 ± 44, these are effectively inconsequential improvements for a substantial increase in
screening time. Alternatively, false negatives in the binding assay (missed tight binders)
may be potentially detrimental to proteins that bind a very limited number of ligands (< 5).
In principal, a single false negative may be the difference between a significant or
insignificant E-value. Of course, the number of binders is expected to scale with the library
size, assuming a relatively constant hit rate.38 Correspondingly, increasing the library size to
1500–2000 compounds is expected to make proteins that bind only four or less ligands a
relatively rare event.
Correlating Protein Function with Ligand Binding Profiles
To experimentally support the ligand binding profile hypothesis, 19 proteins were screened
by NMR using our chemical library of biologically active compounds.27 Binding events
were identified as previously described by measuring a decrease in ligand 1H NMR peak
intensities in the presence of a protein (Figure 2a).4, 25 Thus, the ligand binding profile is
simply a binary list that indicates which compounds out of the library of 437 compounds
were shown to bind the protein. The complete summary of results from the NMR ligand
affinity screen for the 19 proteins can be found in Table 1S.
For the 19 proteins screened in the NMR ligand affinity assay, 13 proteins have a previously
annotated function based on GO terms and 6 proteins have an unknown function. The 19
proteins were chosen to contain two sets of functionally similar proteins mixed with a third
set of functionally diverse proteins. The two sets of functionally related proteins are 2 serum
albumins and 5 amylases. The serum albumins and amylases were chosen because the
proteins have a function related to ligand binding and were readily available from
commercial sources. The additional 12 proteins are from NESG or other on-going functional
annotation projects involving our FAST-NMR methodology.4, 14 The primary intent of these
additional proteins is to provide a “functional background” to test the ability of the ligand
binding profile to distinguish the serum albumins and amylases from each other and from
the remaining proteins. Will the addition of the 12 functionally diverse proteins cause
erroneous similarities to the albumins or amylases that is not correlated with function?
A FunSimMat functional similarity score was calculated for each pair of proteins within the
set of 19 proteins.32 FunSimMat uses GO terms to generate a semantic similarity score that
ranges from 0 for no functional similarity to 1 for identical functions. An average
FunSimMat similarity score of 0.98 and 0.67 ± 0.04 was calculated between the albumins
and amylases, respectively. The remaining 12 proteins exhibited no functional relationship
to any other protein in the screening set, yielding an average FunSimMat similarity score of
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0.1 ± 0.1. The complete list of FunSimMat similarity scores can be found in Table 2S. A
weak functional similarity was observed between the two albumins and the human protein
ubiquitin-fold modifier-conjugating enzyme 1 (UFC1, Uniprot: Q9Y3C8). However, this
similarity is limited to one overlapping and generic “protein binding” GO number (GO:
0005515).
An all-vs-all pairwise comparison of the 19 ligand binding profiles gave a total of 171 ligand
binding profile comparisons with only 11 comparisons giving a significant similarity score
(P < 0.0001). The comparisons with the highest similarity scores corresponded to the set of
albumins (E-value 1×10−58) and the set of amylases (median E-value 3×10−13). Conversely,
the median E-value for the remaining ligand binding comparisons was 0.1. For comparison,
a median E-value of 3×10−26 was obtained when all the ligand binding profiles are
compared to themselves. These results clearly indicate that ligand binding profile
similarities are strongly correlated with functional similarity. All the protein pairs with a
significant ligand binding similarity score along with the corresponding FunSimMat
functional similarity score are listed in Table 1. The complete list of ligand binding
similarity scores can be found in Table 3S. It is also important to note that the absolute
magnitude of a ligand binding profile E-value is directly dependent on the total number of
ligands shown to bind a protein. This is equivalent to sequence homology where the E-value
scales by the length of the protein sequences.
The overall similarity in the ligand binding profiles is also easily visualized in a heat map
(Figure 2b). A ligand identified by NMR to bind a protein is simply indicated by a red line
in the heat map. The ligands are sorted first by their ability to bind human serum albumin
(HSA) and then by their binding to A. oryzae α-amylases (Aor). An expansion of the heat
map focused on the amylases and sorted by ligand binding to Aor is also shown in Figure 3.
The heat map clearly shows overlapping clusters of ligands between the albumins and
amylases. The remainder of proteins exhibits no similarity in the ligand binding profile
based on the obvious random scatter in the heat map.
There was also a minimal similarity in ligand binding between S. aureus nuclease and the α-
amylases from A. oryzae and B. amyloliquefaciens (median E-value 4×10−5). It is plausible
that this minimal similarity is simply due to a serendipitous overlap in non-specific ligand
binding between the three proteins. However, the similarity in the ligand binding profiles
was limited to the nucleosides in the library. Additionally, the remaining 3 amylases did not
bind these ligands or exhibit a significant ligand binding similarity to nuclease. The
observed ligand binding similarity between the nuclease and two of the α-amylases is
potentially due to trace amounts of a nuclease that may be present in the A. oryzae and B.
amyloliquefaciens α-amylases samples. This is a likely occurrence since the samples were
purchased as crude mixtures, where size-exclusion chromatography only yielded a modest
improvement in purity. This illustrates an important consideration in the general application
of ligand binding profiles. False positives in the ligand affinity assay due to impurities, non-
specific binding, or experimental concerns (precipitation, aggregation, etc.) may lead to an
inaccurate functional assignment. Proper care in the execution and analysis of ligand binding
profiles should minimize these concerns.
As shown in table 1, HSA and BSA had a large number of binding ligands (178 and 171,
respectively) compared to the overall size of the library. The relative hit rate for these two
proteins was 40.7% and 39.1% respectively. With a large hit rate, false similarities may arise
if a second protein serendipitously binds to a small subset of compounds that were shown to
bind HSA or BSA. However, the ligand binding similarity score (eqn. 2) effectively
eliminates this concern by scaling the score based on both the total number of compounds
found to bind each protein and by the number of overlapping binding ligands. As an
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example, the S. typhimurium type III secretion system protein PrgI bound to a total of five
compounds, where each compound was also shown to bind HSA and BSA. The
corresponding E-values for the ligand binding profile comparisons between PrgI and HSA
(7 × 10−2) and BSA (6 × 10−2) were not significant at a P=0.0001.
Ligand binding profiles are independent of sequence and structural information and thus
provide an experimentally based approach to predict protein function in a relatively robust
and high-throughput fashion. The results reported herein demonstrate a clear correlation
between ligand binding similarity scores and FunSimMat functional similarity scores.
Specifically, only the set of albumins and amylases gave significant ligand binding
similarity scores. Unfortunately, the ligand binding profiles were unable to differentiate
between the two α and β amylase families. A further refinement of the functional annotation
would require a second screening step using a focused library to differentiate these
functional classes. In the case of the amylases, this would involve screening the proteins
with a carbohydrate library, where a subset of the compounds would selectively bind to the
α- or β-amylase proteins. Alternatively, a larger chemical library with an increase in the
number of compounds per representative class, such as additional carbohydrates, would be
expected to enhance the functional resolution of the technique.
While our methodology has been shown to be effective with the proteins examined,
limitations may be encountered with other classes of proteins. An NMR ligand affinity
screen using intrinsically disordered proteins would be unproductive unless ligand binding
induced a folded state or a binding partner that stabilized a folded state was present. Of
course, the presence of a binding partner would complicate the data analysis; does the ligand
bind the complex or binding partner instead of the targeted protein? Membrane proteins
would be equally challenging, requiring methods to prepare adequate quantities of the
protein for the NMR screen while requiring lipid bicelles, micelles or detergents to stabilize
the protein. A similar data analysis problem would arise. Do the ligands interact with the
lipid bicelles, micelles or detergents instead of or in addition to the protein target?
Furthermore, does the NMR sample preparation procedure affect the solubility or
aggregation state of compounds in the library? Finally, proteins that bind a very limited
number of compounds from our library (< 5) would result in a ligand binding profile that
would only yield insignificant E-values (> 1×10−9). Despite these potential limitations and
challenges, ligand binding profiles are expected to be broadly applicable to the majority of
the proteome.
CONCLUSION
The success of whole-genome sequencing has generated an enormous dataset of functionally
uncharacterized proteins. Sequence and structure homology are routinely used to leverage
functional annotations, but > 30% of the proteome lack a sequence or structure similarity to
proteins of known function. Alternatively, detailed experimental analysis may require
upwards of a decade of effort to characterize a single protein. Instead, we describe the use of
high-throughput (HTS) NMR ligand affinity screens to infer a biological function through a
similarity in ligand binding profiles. A diverse chemical library is used to map the
physiochemical properties of a protein’s active-site, where the identity of the ligands that
bind a protein provides information about the biological activity of the protein. A
modification to the E-value developed by Karlin and Altschul allows for a similarity
between ligand-binding profiles to be measured, where an E-value ≤ 1×10−9 suggests
functional homologs. We demonstrated that the preponderance of binding ligands identified
from 19 NMR ligand affinity screens were uniquely associated with each functional class
and were shown to correlate with the protein’s function based on GO terms (Figure 2b and
Table 1).
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Figure 1.
(A) Three dimensional PCA scores plot where each point represents one compound from the
functional chemical library. The placement of each point in the PCA scores plot is indicative
of the unique structural identity for each compound. The contribution of each principal
component is labeled on the axis. The sphere represents the 95% confidence limit. (B) A
histogram distribution of E-values calculated from a simulation of ligand binding profiles. A
random ligand-binding profile was compared against a random set of 1×106 ligand binding
profile using a library of 437 compounds. The solid line corresponds to the best fit curve
from the Weibull Distribution (Extreme Value Type III Distribution) model. (C) A plot of
the percentage of false negatives as a function of error rate (10% to 50%) and library size
(437 to 10,000) from a simulation of ligand-binding profiles.
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Figure 2.
(A) Ligand binding is identified by a decrease in ligand peak intensity upon addition of a
target protein. The 1D 1H NMR spectrum of the non-steroidal anti-inflammatory drug
naproxen (I) is shown to broaden in the presence of H. sapiens serum albumin (HSA) (II)
and B. Taurus serum albumin (BSA) (III) indicating a positive binding event. The NMR
line broadening experiments used 100 μM ligand and 5 μM protein as described in the
methods section. (B) Heat map summarizing the NMR ligand affinity screens for 19
proteins: where the albumins are colored red, the amylases cyan and the remainder of the
proteins gray. A binding ligand is indicated by a red line. The 437 ligands were sorted to
maximize the clustering of binding ligands for the albumins and amylases.
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Figure 3.
Expanded view of the heat map shown in Figure 2 highlighting the similarity in ligand
binding profiles for the amylases. The 437 ligands were sorted to maximize the clustering of
binding ligands for the amylases.
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molID  commonName  plate  well  priMix HSA BSA Aor Bam Bli Iba Hvu Nuc DnaG PrgI Sav1430 YtfP PA1324 YkvR YkfF STM1790 DGKA YjbR UFC1
2 Adenosine 5-triphosphate disodium salt (ATP) 1 A1 1001 1-Methylimidazole  1-Methylimidazole   L-Leucineb-naphthylamide   L-Leucineb-naphthylamide  5-Bromo-4-chloro-3-indolylb-D-galactopyranoside Sodium glycocholate hydrate (Bile salt)
  (±)-6-Methyl-5,6,7,8-tetrahydropterine 
dihydrochlorid; (Tetrahydropteridine)
4-Hydroxy-3-methoxyphenylglycol sulfate potassium 
salt
 1-Methylimidazole  1-Methylimidazole  5-Fluoro-5'-deoxyuridine Adenine (Vitamine B4) [Hydroxy(tosyloxy)iodo]benzene 3,5-Dinitrocatechol Amoxicillin Pepstatin A
Guanosine 3',5'-cyclic monophosphate sodium salt 
(cyclic GMP)
Cytidine 5'-triphosphate disodium salt (CTP) L-Histidine (His)
3 Cytidine 5'-triphosphate disodium salt (CTP) 1 B1 1002 5-Fluoro-5'-deoxyuridine  5-Fluoro-5'-deoxyuridine   N-Acetylprocainamide hydrochloride  5-Bromo-4-chloro-3-indolylb-D-galactopyranoside (-)-Peril l ic acid Doxycycline hyclate   L-Leucineb-naphthylamide Acebutolol hydrochloride  (±)-a-Lipoamide Didecyldimethylammonium bromide (±)-Thalidomide Amoxicillin 2',3'-Dideoxyadenosine Adenine (Vitamine B4) Cyclo(His-Pro)
Methyl 6,7-dimethoxy-4-ethyl-b-carboline-3-
carboxylate
Adenine (Vitamine B4, 6-Aminopurine) Doxycycline hyclate suramin
4 Guanosine 5'-triphosphate sodium salt hydrate (GTP) 1 C1 1003 (-)-Perillic acid (-)-Perillic acid  1,3-Dimethyluric acid 2-Amino-4-methylphenol 1-Phenyl-1-cyclopropanecarboxylic acid -Nicotinamide adenine dinucleotide (NAD+, NADH)   O-Phospho-L-tyrosine Adenosine 3',5'-cyclic monophosphate (cyclic AMP) (±)-Propranolol hydrochloride L-Carnitine inner salt (vitamin Bt) 2',3'-Dideoxyadenosine Diminazene aceturate (Berenil) 2-Aminothiazol Amoxicillin Ethacridine
Flavin adenine dinucleotide disodium salt dihydrate
flavin adenine dinucleotide (FAD, FADH2)
Adenosine 5'-monophosphoric acid monohydrate Nalidixic acid sodium salt Aminophylline hydrate
5 Thymidine 5'-triphosphate sodium salt (TTP) 1 D1 1004 (±)-2,3-Dichloro-a-methylbenzylamine hydrochloride [Hydroxy(tosyloxy)iodo]benzene  5-Bromo-4-chloro-3-indolylb-D-galactopyranoside 2'-Deoxyadenosine 5'-monophosphate 2'-Deoxyadenosine 5'-monophosphate
Flavin adenine dinucleotide disodium salt dihydrate
flavin adenine dinucleotide (FAD, FADH2)
2-Amino-4-methylphenol Adenosine 5'-triphosphate disodium salt (ATP) 3-Aminopropionitrile fumarate salt Methiothepin mesylate salt 2'-Deoxyadenosine 5'-monophosphate Eserine (Physostigmine) 2-Ethylimidazole histamine L-2-Aminoadipic acid L-Glutamic acid (Glu) Novobiocin sodium salt *IN FREEZER suramin Rifampicin 
6 Uridine 5'-triphosphate trisodium salt dihydrate (UTP) 1 E1 1005 (±)-Carnitine chloride 1-(4-Chlorobenzyl)-5-methoxy-2-methylindole-3-acetic acid (-)-Peril l ic acid 3-Methyladenine 4-Deoxypyridoxine hydrochloride   O-Phospho-L-tyrosine 2'-Deoxyadenosine 5'-monophosphate Aquocobalamin 5,5-Diphenylhydantoin sucrose 3-(1-Naphthyl)-D-alanine Kaempferol
4-(2-Aminoethyl)benzenesulfonyl fluoride 
hydrochloride
L-2-Aminoadipic acid Lidocaine hydrochloride 1-Methylhistamine dihydrochloride Acridine Orange base Adenosine 3',5'-cyclic monophosphate (cyclic AMP) 4-Methylpyrazole hydrochloride
7 Adenosine 3',5'-cyclic monophosphate (cyclic AMP) 1 F1 1006 (±)-Propranolol hydrochloride 1,3-Dimethyluric acid 1-Phenyl-1-cyclopropanecarboxylic acid 4-Deoxypyridoxine hydrochloride 5-Phenylvaleric acid Penicil l in G potassium salt (benzyl penicil l in) 3,5-Dinitrocatechol Bepridil hydrochloride  Acycloguanosine 4-Chloromercuribenzoic acid L-2-Aminoadipic acid 4-Hydroxytamoxifen Sodium citrate tribasic dihydrate Lorglumide sodium salt Acycloguanosine
6,9-Diamino-2-ethoxyacridine-DL-lactate 
monohydrate
Thiamine pyrophosphate (TPP) Bay 11-7085
8 Guanosine 3',5'-cyclic monophosphate sodium salt (cyclic GMP) 1 G1 1007 [Hydroxy(tosyloxy)iodo]benzene 1-Aminocyclopropanecarboxylic acid 2'-Deoxyadenosine 5'-monophosphate
4-Hydroxy-3-methoxyphenylglycol sulfate potassium 
salt
6,9-Diamino-2-ethoxyacridine-DL-lactate 
monohydrate
Rifampicin 4-Methylpyrazole hydrochloride Ciprofloxacin Chelerythrine chloride 6,7-Dimethyl-5,6,7,8-tetrahydropterine hydrochloride Lidocaine hydrochloride 5a-Androstane-3,17-dione Bay 11-7085 Orange II sodium salt 1-Methylhistamine dihydrochloride 3,5-Dinitrocatechol
9 N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide 1 H1 1050 1-(4-Chlorobenzyl)-5-methoxy-2-methylindole-3-acetic acid 1-Methylhistamine dihydrochloride
4-Hydroxy-3-methoxyphenylglycol sulfate potassium 
salt
6,9-Diamino-2-ethoxyacridine-DL-lactate 
monohydrate
6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide Acridine Orange base Cytidine 5'-triphosphate disodium salt (CTP) Didecyldimethylammonium bromide 6-Amino-3-methylpurine N-Acetyl-L-tryptophan_3-5-trifluoromethyl_benzyl_ester a-Methyl-DL-tyrosine Bromophenol Blue 3-Chlorophenol Bepridil hydrochloride  Acridine Orange base
10 Coenzyme A sodium salt hydrate 1 A2 1009 1,3-Dimethyluric acid 1-Phenyl-1-cyclopropanecarboxylic acid 4-Methylpyrazole hydrochloride Acridine Orange base Acridine Orange base L-Arginine (Arg) Adenosine 5'-monophosphoric acid monohydrate Diminazene aceturate L-Histidine (His) 6-Hydroxydopamine hydrochloride (6-hydroxyDOPA) Novobiocin sodium salt Bay 11-7085 Uridine 5'-monophosphate Prednisolone  5-Bromo-4-chloro-3-indolylb-D-galactopyranoside Bromophenol Blue
11 DL-Pantothenic acid hemicalcium salt Pantothenate (vitamin B5) 1 B2 1010 1-Aminocyclopropanecarboxylic acid
1-Phenylcyclopentanecarboxylic acid 2-(2-
diethylaminoethoxy)ethyl ester citrate salt
5-Phenylvaleric acid Adenosine 5'-monophosphoric acid monohydrate Bisbenzimide H 33258 Phospho(enol)pyruvate potassium salt -Methyl-DL-tyrosine
Guanosine 3',5'-cyclic monophosphate sodium salt 
(cyclic GMP)
mitoxantrone dihydrochloride Adenosine 3',5'-cyclic monophosphate (cyclic AMP) Orange II sodium salt Bromophenol Blue Bisbenzimide H 33258  1,3-Dimethyluric acid histamine Adenine (Vitamine B4, 6-Aminopurine)
12 b-Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt (NADP+,NADPH) 1 C2 1011 1-Methylhistamine dihydrochloride 2,3,5-Triiodobenzoic acid 
6,9-Diamino-2-ethoxyacridine-DL-lactate 
monohydrate
Adenosine 5'-triphosphate disodium salt (ATP) Bromophenol Blue Carbetapentane citrate salt Bisbenzimide H 33258 Guanosine 5'-triphosphate sodium salt hydrate (GTP) Sodium creatine phosphate dibasic tetrahydrate a-Methyl-DL-tyrosine Phenol Red Carbobezoxy-valinyl-phenylalaninal Didecyldimethylammonium bromide Chlortetracycline hydrochloride Bromophenol Blue Hydralazine hydrochloride
13 b-Nicotinamide adenine dinucleotide (NAD+, NADH) 1 D2 1012 1-Phenyl-1-cyclopropanecarboxylic acid 2-Amino-4-methylphenol Acebutolol hydrochloride  Bisbenzimide H 33258 Carbetapentane citrate salt  5-Bromo-4-chloro-3-indolylb-D-galactopyranoside Bromophenol Blue L-Leucine (Leu) Sodium DL-lactate   Biotin (vitamin H) progesterone Chlorpropamide Resveratrol 6-Phosphogluconic acid trisodium salt N-Propyl-1,3-propanediamine 2',3'-Dideoxyadenosine
14 Thiamine hydrochloride (Vitamin B1) 1 E2 1013
1-Phenylcyclopentanecarboxylic acid 2-(2-
diethylaminoethoxy)ethyl ester citrate salt
2-Amino-5-methylthiazole Acridine Orange base -Nicotinamide adenine dinucleotide (NAD+, NADH) Chlortetracycline hydrochloride N-Acetyl-L-tryptophanamide Ciprofloxacin Lumicolchicine b-Nicotinamide adenine dinucleotide (NAD+, NADH) Tetracycline Diminazene aceturate Tyrphostin 1 3-Hydroxy-DL-kynurenine Adenine (Vitamine B4, 6-Aminopurine) 2-Methylimidazole
15 Thiamine pyrophosphate (TPP) 1 F2 1014 2,3,5-Triiodobenzoic acid 2-Aminofluorene Adenosine 5'-monophosphoric acid monohydrate Bromophenol Blue Ciprofloxacin Methiothepin mesylate salt Cyclo(His-Pro) mitoxantrone dihydrochloride
b-Nicotinamide adenine dinucleotide phosphate reduced 
tetrasodium salt
Ellipticine 1-Octanol 7-Deazaguanine Clofibrate
Menadione (2-Methyl-1,4-naphthoquinone, vitamin 
k3)
16 Tetrahydrofolate (Folic acid, vitamin M) Pteroyl-L-glutamic acid 1 G2 1015 2-Amino-4-methylphenol 2-Aminopyridine Adenosine 5'-triphosphate disodium salt (ATP) Carbetapentane citrate salt Dansylcadaverine 2,3,5,6, Tetramethyl-P-Benzoquinone (Duroquinone) Dansylcadaverine Phosphocholine chloride calcium salt tetrahydrate Bromophenol Blue Menadione (vitamin k3) Aquocobalamin trans-4-(Aminomethyl)cyclohexanecarboxylic acid
Menadione (2-Methyl-1,4-naphthoquinone, vitamin 
k3)
Didecyldimethylammonium bromide
17 Cyanocobalamin (Vitamin B12) 1 H2 1008 2-Amino-5-methylthiazole 2-Chlorodimedone -Methyl-DL-tyrosine Ciprofloxacin Dansylglycin Bromophenol Blue Didecyldimethylammonium bromide suramin Carbetapentane citrate salt Nicotinic acid (Niacin,vitamin B) Ebselen Dipyrone
3-(1-Naphthyl)-D-alanine
 1-Methylimidazole
19 Pyridoxine (Vitamin B6) 1 B3 1018 2-Aminofluorene 2'-Deoxyadenosine 3'-monophosphate Bisbenzimide H 33258 Cytidine 5'-triphosphate disodium salt (CTP) Deoxyadenosyl cobalamin (Vitamin B12) Dansylcadaverine
DL-Pantothenic acid hemicalcium salt
Pantothenate (vitamin B5)
Thymidine 5'-triphosphate sodium salt (TTP) Cytidine 5'-monophosphate Pepstatin A 2,6-Diisopropylphenol - LIQUID Flutamide 2-Aminopyridine
20 6,7-Dimethyl-5,6,7,8-tetrahydropterine hydrochloride 1 C3 1048 2-Aminopyridine 2'-Deoxyadenosine 5'-monophosphate -Nicotinamide adenine dinucleotide (NAD+, NADH) Dansylcadaverine Didecyldimethylammonium bromide Thymidine 5'-monphosphate L-Lysine (Lys) Uridine 5'-triphosphate trisodium salt dihydrate (UTP) Dobutamine hydrochloride PMSF, Phenylmethanesulfonyl fluoride Nadolol Diminazene aceturate Resveratrol
21 Flavin adenine dinucleotide disodium salt dihydrate flavin adenine dinucleotide (FAD, FADH2) 1 D3 1020 2-Chlorodimedone 2-Ethylimidazole Bromophenol Blue Deoxyadenosyl cobalamin (Vitamin B12)
Flavin adenine dinucleotide disodium salt dihydrate
flavin adenine dinucleotide (FAD, FADH2)
Pyridoxal 5'-phosphate Lorglumide sodium salt Ethacridine suramin PTH-tryptophan Aquocobalamin
23 Nicotinic acid (Niacin,vitamin B) 1 F3 1022 2'-Deoxyadenosine 3'-monophosphate 2-Methylimidazole Carbetapentane citrate salt Didecyldimethylammonium bromide Guanosine 5'-triphosphate sodium salt hydrate (GTP) 2-Amino-4-methylphenol Lumicolchicine Genistein Tyrphostin 25 Lumicolchicine
24 D-(+)-Neopterin 1 G3 1051 2'-Deoxyadenosine 5'-monophosphate 3,3',5-Triiodothyroacetic acid Ciprofloxacin Diminazene aceturate Hydrocortisone (cortisol) Bisbenzimide H 33258 Methotrexate hydrate L-Lysine (Lys), (S)-(+)-lysine (±)-Camphor
25 6-Hydroxydopamine hydrochloride (6-hydroxyDOPA) 1 H3 1016 2-Ethylimidazole 3,4-Dimethylaniline Clofibrate
Flavin adenine dinucleotide disodium salt dihydrate
flavin adenine dinucleotide (FAD, FADH2)
L-Glutamine (Gln) 2'-Deoxyadenosine 5'-monophosphate N-Acetyl-L-tryptophanamide Lonidamine Homovanill ic acid
26 Sodium glycocholate hydrate (Bile salt) 1 A4 1001 2-Methylimidazole 3,4-Dimethylphenol Cytidine 5'-triphosphate disodium salt (CTP)
Guanosine 3',5'-cyclic monophosphate sodium salt 
(cyclic GMP)
L-Glutathione reduced N-Acetylneuraminic acid N-Vanillylnonanamide Lorglumide sodium salt Cephalexin hydrate
27 L-Glutathione reduced 1 B4 1002 3,3',5-Triiodothyroacetic acid
3-Hydroxy-4-methoxyphenethylamine hydrochloride, 4-
Methoxytyramine hydrochloride
Dansylcadaverine Guanosine 5'-triphosphate sodium salt hydrate (GTP) N-Acetyl-L-tryptophanamide Phosphocholine chloride calcium salt tetrahydrate Phosphocholine chloride calcium salt tetrahydrate Methiothepin mesylate salt 1-Octanol
28 (±)-6-Methyl-5,6,7,8-tetrahydropterine dihydrochloride; (Tetrahydropteridine) 1 C4 1003 3,4-Dimethylaniline 3-Isobutyl-1-methylxanthine Dansylglycin Hydrocortisone (cortisol) N-tert-Butyl-a-phenylnitrone Ciprofloxacin Pyridoxal 5'-phosphate Novobiocin sodium salt  (±)-Verapamil hydrochloride
29 Biotin (vitamin H) 1 D4 1004 3,4-Dimethylphenol 3-Methoxytyramine hydrochloride Deoxyadenosyl cobalamin (Vitamin B12) Hydrocortisone (cortisol) Penicil l in G potassium salt (benzyl penicil l in) Diminazene aceturate S-(-)-Carbidopa O-Phospho-L-tyrosine Tetracycline
30 Methoxatin (PQQ) 1 E4 1005
3-Hydroxy-4-methoxyphenethylamine hydrochloride, 4-
Methoxytyramine hydrochloride
4-Deoxypyridoxine hydrochloride Didecyldimethylammonium bromide Methotrexate hydrate Pentoxifyll ine
4-Hydroxy-3-methoxyphenylglycol sulfate potassium 
salt
Thymidine 5'-monphosphate ouabain
2,6-Diisopropylphenol - LIQUID
31 4-Phenylazobenzyloxycarbonyl-Pro-Leu-Gly-Pro-D-Arg 1 F4 1053 3-Isobutyl-1-methylxanthine 4-Guanidinobutyric acid
D-Panthenol (R)-(+)-2,4-Dihydroxy-N-(3-
hydroxypropyl)-3,3-dimethylbutyramide) *IN 
mitoxantrone dihydrochloride Phosphocholine chloride calcium salt tetrahydrate Lumicolchicine Uridine 5'-monophosphate Praziquantel
Bithionol
32 N-tert-Butyl-a-phenylnitrone 1 G4 1050 3-Methoxytyramine hydrochloride 4-Hydroxytamoxifen Eserine (Physostigmine) N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide Cimetidine Uridine 5'-triphosphate trisodium salt dihydrate (UTP) Resorufin
33 PABA, vitamin H1 1 H4 1008 4-Deoxypyridoxine hydrochloride 4-Methylpyrazole hydrochloride
Flavin adenine dinucleotide disodium salt dihydrate
flavin adenine dinucleotide (FAD, FADH2)
Phosphocholine chloride calcium salt tetrahydrate Sodium palmitate
34 L-Carnitine inner salt (vitamin Bt) 1 A5 1009 4-Guanidinobutyric acid 5,5-Diphenylhydantoin Hydrocortisone (cortisol) Pyridoxal 5'-phosphate
36 S-(5'-Adenosyl)-L-methionine chloride 1 C5 1011 4-Hydroxy-3-methoxyphenylglycol sulfate potassium salt 5a-Androstane-3,17-dione
Menadione (2-Methyl-1,4-naphthoquinone, vitamin 
k3)
S-(-)-Carbidopa *IN SUBZERO
38 L-Aspartic acid (Asp) 1 D5 1012 4-Hydroxytamoxifen 5-Hydroxyindole-3-acetic acid mitoxantrone dihydrochloride Sodium cacodylate trihydrate
39 L-Alanine (Ala) 1 E5 1013 4-Methylpyrazole hydrochloride Acebutolol hydrochloride Nalidixic acid sodium salt Thymidine 5'-monphosphate
40 L-Leucine (Leu) 1 F5 1006 5,5-Diphenylhydantoin Acetazolamide Phosphocholine chloride calcium salt tetrahydrate Thymidine 5'-triphosphate sodium salt (TTP)
41 L-Isoleucine (Ile) 1 G5 1007 5a-Androstane-3,17-dione Acetylsalicylic acid  (aspirin) Thymidine 5'-monphosphate
42 L-Tyrosine 1 H5 1016 5-Hydroxyindole-3-acetic acid Acetylthiocholine chloride
43 L-Tryptophan (Trp) 1 A6 1017 6,7-Dimethyl-5,6,7,8-tetrahydropterine hydrochloride Acycloguanosine 
44 L-Serine (Ser) 1 B6 1018 Acebutolol hydrochloride Adenosine 3',5'-cyclic monophosphate (cyclic AMP)
45 L-Threonine 1 C6 1019 Acetazolamide AEBSF
46 L-Glutamic acid (Glu), (S)-(+)-Glutamic acid 1 D6 1020 Acetylsalicylic acid  (aspirin) Aflatoxin B1
47 L-Glutamine 1 E6 1021 Acetylthiocholine chloride Alaproclate hydrochloride
48 L-Methionine (Met) 1 F6 1022 Acycloguanosine Amantadine hydrochloride
49 L-Proline (Pro) 1 G6 1023 Adenosine 3',5'-cyclic monophosphate (cyclic AMP) Ampicillin
50 trans-4-Hydroxy-L-proline 1 H6 1024 AEBSF Androstenedione  
51 L-Arginine (Arg) 1 A7 1009 Aflatoxin B1 Antipyrine
52 L-Lysine (Lys), (S)-(+)-lysine 1 B7 1010 Alaproclate hydrochloride AY 9944
53 L-Histidine (His) 1 c7 1011 Amantadine hydrochloride benzamide
54 O-Phospho-L-serine 1 D7 1012 Ampicillin Benzamidine hydrochloride hydrate
55 O-Phospho-L-tyrosine 1 E7 1013 Androstenedione  Benzoic acid
56 PMSF 1 F7 1014 Antipyrine Benzylamine
57 AEBSF 1 G7 1015 AY 9944 Bestatin hydrochloride
58 4-Chloromercuribenzoic acid 1 H7 1016 benzamide Bisbenzimide H 33258
59 Phosphoramidon disodium salt 1 A8 1052 Benzoic acid Bithionol
60 Pepstatin A 1 B8 1018 Benzylamine b-Nicotinamide adenine dinucleotide (NAD+, NADH)
61 Daphnetin 1 C8 1019 Bisbenzimide H 33258 Brefeldin A
62 suramin sodium salt 1 D8 1020 Bithionol Bromocresol Green
63 2,3-diphosphoglycerate pentasodium salt 1 E8 1069 Brefeldin A Bromophenol Blue
64 Penicillin G potassium salt (benzyl penicillin) 1 F8 1022 Bromocresol Green Camptothecin 
65 Rifampicin 1 G8 1023 Bromophenol Blue Carbamazepine
66 Puromycin dihydrochloride hydrate 1 H8 1024 Camptothecin Chelerythrine chloride
67 cycloheximide 1 A9 1001 Carbamazepine Chelidamic acid
68 cytochalasin B 1 B9 1002 Chelerythrine chloride Chloramphenicol
69 colchicine 1 C9 1003 Chelidamic acid Chlorpropamide
70 Acetylsalicylic acid (aspirin) 1 D9 1004 Chloramphenicol Choline phosphate chloride
71 ouabain 1 E9 1005 Chlorpropamide Chymostatin
72 neostigmine 1 F9 1006 Choline phosphate chloride Cimetidine
73 N-Phospho-Ile(O-ethyl)-Tyr(O-benzyl)-Gly dipotassium salt 1 G9 1007 Chymostatin Cinoxacin
74 MDL 28170 Carbobezoxy-valinyl-phenylalaninal 1 H9 1008 Cimetidine Clenbuterol hydrochloride
75 Cantharidin 1 A10 1009 Cinoxacin clofibrate
76 Calmidazolium chloride 1 B10 1010 Clenbuterol hydrochloride Coenzyme A sodium salt hydrate
77 Sodium oxamate 1 C10 1054 clofibrate colchicine 
78 Chymostatin 1 D10 Coenzyme A sodium salt hydrate compound
79 Ellipticine 1 E10 1049 colchicine Cordycepin
80 Aminophylline hydrate 1 F10 1014 Cordycepin Cromolyn sodium salt 
81 erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride 1 G10 1015 Cromolyn sodium salt cycloheximide
82 Ceftriaxone sodium salt 1 H10 1016 Curcumin Cyproheptadine
83 Cinoxacin 1 A11 1001 cycloheximide Cytidine 5'-monophosphate
84 Doxycycline hyclate Doxycycline hydrochloride hemiethanolate hemihydrate 1 B11 1002 Cyproheptadine Cytidine 5'-triphosphate disodium salt (CTP)
85 Nalidixic acid sodium salt 1 C11 1003 Cytidine 5'-monophosphate Dansylcadaverine
86 Cytosineb-D-arabinofuranoside 1 D11 1053 Cytidine 5'-triphosphate disodium salt (CTP) Dansylglycin
87 Praziquantel 1 E11 1005 Dansylcadaverine Daphnetin
88 Ethosuximide 1 F11 1006 Dansylglycin Diclofenac sodium salt
89 L-Methionine sulfoximine 1 G11 1052 Daphnetin Didecyldimethylammonium bromide
90 8-Methoxypsoralen 1 H11 1008 Diclofenac sodium salt Digitoxin
91 2-Chlorodimedone 1 A12 1052 Didecyldimethylammonium bromide Dipyrone
92 DMCM Methyl-6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate 1 B12 1018 Digitoxin
DL-Pantothenic acid hemicalcium salt   Pantothenate (vitamin 
B5)
93 Acetamide 1 C12 1011 Dipyrone DL-Thiorphan
95 4-Aminobenzamidine dihydrochloride 1 E12 1021
DL-Pantothenic acid hemicalcium salt   Pantothenate (vitamin 
B5)
Dobutamine hydrochloride
96 Chelerythrine chloride 1 F12 1051 DL-Thiorphan erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride
97 Benzamidine hydrochloride hydrate 1 G12 1007 Dobutamine hydrochloride Ethosuximide
98 Diethylenetriaminepentaacetic acid 1 H12 1024 erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride Ethyl 3-pyridineacetate
99 Boc-L-phenylalaninol 2 A1 1049 Ethosuximide Flutamide
100 4-Methylpyrazole hydrochloride 2 B1 1026 Ethyl 3-pyridineacetate Furosemide
101 benzamide 2 C1 1070 Flutamide Griseofulvin
102 Bepridil hydrochloride 2 D1 1020 Furosemide
Guanosine 3',5'-cyclic monophosphate sodium salt (cyclic 
GMP)
103 Indomethacin morpholinylamide 2 E1 1021 Griseofulvin Guanosine 5'-triphosphate sodium salt hydrate (GTP)
104 Bay 11-708 2 F1 1022
Guanosine 3',5'-cyclic monophosphate sodium salt (cyclic 
GMP)
Homovanillic acid
105 Mitoxantrone dihydrochloride 2 G1 1050 Guanosine 5'-triphosphate sodium salt hydrate (GTP) Hydrochlorothiazide
106 Ribavirin 2 H1 1024 Homovanillic acid Ibuprofen
107 Allopurinol 2 A2 1017 Hydrochlorothiazide Idazoxan hydrochloride
108 Lonidamine 2 B2 1026 Ibuprofen Indomethacin
109 Lorglumide sodium salt 2 C2 1019 Idazoxan hydrochloride Inosine 5'-monophosphate disodium salt
110 Atropine sulfate salt hydrate 2 D2 1028 Indomethacin Kynurenic acid
111 N-Phenylanthranilic acid 2 E2 1021 Inosine 5'-monophosphate disodium salt L-Alanine (Ala)
112 (±)-Thalidomide 2 F2 1030 Kynurenic acid L-Aspartic acid (Asp)
113 (-)-Perillic acid 2 G2 1070 L-Alanine (Ala) L-Carnitine inner salt (vitamin Bt)
114 3-Amino-2,3-dihydrobenzoic acid hydrochloride 2 H2 1032 L-Arginine (Arg) L-Glutathione reduced
115 L-2-Aminoadipic acid 2 A3 1017 L-Carnitine inner salt (vitamin Bt) L-Leucine (Leu)
116 Chelidamic acid 2 B3 1026 L-Glutathione reduced L-Leucine-2-naphthylamide
117 Idazoxan hydrochloride 2 C3 1019 Lidocaine hydrochloride Lorglumide sodium salt
118 3'-Azido-3'-deoxythymidine 2 D3 1028 L-Leucine (Leu) L-Pipecolic acid
119 Acycloguanosine 2 E3 1106 L-Leucine-2-naphthylamide L-Tyrosine (Tyr)
120 7,7-Dimethyl-(5Z,8Z)-eicosadienoic acid 2 F3 1030 L-Lysine (Lys), (S)-(+)-lysine Lumicolchicine
121 Ranolazine dihydrochloride 2 G3 1023 Lonidamine Mecamylamine hydrochloride
122 [Hydroxy(tosyloxy)iodo]benzene 2 H3 1052 Lorglumide sodium salt Methiothepin mesylate salt
123 1-(4-Chlorobenzyl)-5-methoxy-2-methylindole-3-acetic acid 2 A4 1047 L-Pipecolic acid Methotrexate, (+)-Amethopterin
124 a-Methyl-DL-tyrosine 2 B4 1026 L-Tyrosine (Tyr) Mycophenolic acid
125 6-Methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole 2 C4 1027 Lumicolchicine N-Acetylneuraminic acid
126 Captopril 2 D4 1028 Mecamylamine hydrochloride Nalidixic acid sodium salt
127 (±)-2,3-Dichloro-a-methylbenzylamine hydrochloride 2 F4 1030 Methiothepin mesylate salt Naproxen
128 3,5-Dinitrocatechol 2 G4 1031 Methotrexate, (+)-Amethopterin neostigmine
129 DL-Thiorphan 2 H4 1068 Mycophenolic acid Netropsin dihydrochloride hydrate
130 Aztreonam 2 A5 1051 N-Acetylneuraminic acid Novobiocin sodium salt
131 Carbetapentane citrate salt 2 B5 1034 Nalidixic acid sodium salt N-Phenylanthranilic acid
132 Naloxone hydrochloride dihydrate 2 C5 1027 Naproxen N-Phospho-Ile(O-ethyl)-Tyr(O-benzyl)-Gly dipotassium salt
133 (-)-Tetramisole hydrochloride 2 D5 1028 neostigmine N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide
134 Chlorzoxazone 2 E5 1029 Netropsin dihydrochloride hydrate N-tert-Butyl-a-phenylnitrone
135 Genistein 2 F5 1030 Nitrendipine O-Phospho-L-tyrosine
136 Methyl-6-O-(N-heptylcarbamoyl)-a-D-glucopyranoside 2 G5 Novobiocin sodium salt Orange II sodium salt
137 Methiothepin mesylate salt 2 H5 1032 N-Phenylanthranilic acid ouabain
138 Sepiapterin 2 A6 1049 N-Phospho-Ile(O-ethyl)-Tyr(O-benzyl)-Gly dipotassium salt Oxacillin
139 N-Acetyl-L-tryptophan 3,5-bis(trifluoromethyl)benzyl ester 2 B6 1034 N-Succinyl-Ala-Ala-Pro-Phe p-nitroanilide p-Aminohippuric acid
140 Picotamide 2 C6 1027 N-tert-Butyl-a-phenylnitrone Pentoxifylline
141 Thioctic acid Lipoic acid 2 D6 1050 N-Vanillylnonanamide Pepstatin A
142  5-Bromo-4-chloro-3-indolylb-D-galactopyranoside 2 E6 1048 O-Phospho-L-tyrosine Phenol Red
143 a-Lactose monohydrate 2 F6 1038 Orange II sodium salt phenylbutazone
144 D(+)-Maltose monohydrate 2 G6 1031 ouabain Phenylpyruvic acid
145 sucrose 2 H6 1032 Oxacillin Picrotin
146 L-Leucine-2-naphthylamide 2 A7 1053 p-Aminohippuric acid Podophyllotoxin
147 Glucose 2 B7 1034 Penicillin G potassium salt (benzyl penicillin) Praziquantel
148 4-Deoxypyridoxine hydrochloride 2 C7 1048 Pentoxifylline Prednisolone 
149 D-Sorbitol 2 D7 1036 Pepstatin A Procaine hydrochloride 
150 Melatonin 2 E7 1029 Phenol Red Psoralen
151 Serotonin hydrochloride 2 F7 1038 phenylbutazone Puromycin dihydrochloride hydrate
152 (1R,2S)-(-)-Ephedrine 2 G7 1031 Phenylpyruvic acid Quercetin dihydrate 
153 (±)-Norepinephrine (+)-bitartrate salt Noradrenaline 2 H7 1032 Picrotin rac-Glycerol 3-phosphate disodium salt
154 (±)-Epinephrine 2 A8 1025 Podophyllotoxin Ranitidine hydrochloride 
155 Dopamine hydrochloride 2 B8 1034 Praziquantel Ranolazine dihydrochloride
156 g-Aminobutyric acid (GABA) 2 C8 1027 Prednisolone Resveratrol
157 Hydrocortisone (cortisol) 2 D8 1036 Procaine hydrochloride Ribavirin
158 caffeine 2 E8 1037 Psoralen Roscovitine
159 progesterone 2 F8 1038 Quercetin dihydrate Silibinin
160 estradiol 2 G8 1023 rac-Glycerol 3-phosphate disodium salt Sodium cacodylate trihydrate
161 vasopressin 2 H8 1040 Ranitidine hydrochloride Sodium creatine phosphate dibasic tetrahydrate
162 acetylcholine 2 A9 1033 Resveratrol Sodium DL-lactate  
163 g-Butyrolactone 2 B9 Ribavirin Sodium glycocholate hydrate (Bile salt)
164 Chlorpropamide 2 C9 1035 Roscovitine Sodium salicylate
165 3-Aminopropionitrile fumarate salt 2 D9 1036 Silibinin succinate
166 Phenylbutazone 2 E9 1037 Sodium cacodylate trihydrate Sulfaphenazole
167 Betaine hydrochloride Trimethyl glycine 2 F9 1038 Sodium citrate tribasic dihydrate suramin
168 Choline bromide 2 G9 1031 Sodium creatine phosphate dibasic tetrahydrate tert-Butyl carbazate
169 (-)-Cotinine 2 H9 1040 Sodium DL-lactate  Theophylline
170 1-Methylhistamine dihydrochloride 2 A10 1068 Sodium glycocholate hydrate (Bile salt) Thiamine hydrochloride (Vitamin B1)
171 Sodium creatine phosphate dibasic tetrahydrate 2 B10 1047 Sodium salicylate Thiamine pyrophosphate (TPP)
172 Lipoic acid 2 C10 1035 succinate Thymidine 5'-monphosphate
173 (±)-a-Lipoamide 2 D10 1036 Sulfaphenazole Timolol maleate salt 
175 N-Acetyl-L-tryptophanamide 2 F10 1044 tert-Butyl carbazate Tolbutamide
176 Sodium citrate tribasic dihydrate 2 G10 1039 Theophylline Tubercidin
177 succinate 2 H10 1040 Thiamine hydrochloride (Vitamin B1) Tyrphostin 1
178 rac-Glycerol 3-phosphate disodium salt 2 A11 1025 Thiamine pyrophosphate (TPP) Warfarin
179 Phospho(enol)pyruvate potassium salt 2 B11 1041 Thymidine 5'-monphosphate
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180 Sodium DL-lactate 2 C11 1035 Timolol maleate salt 
181 Sodium pyruvate 2 D11 1042 Tolbutamide
182 3-Indoleacetic acid 2 E11 1037 Tubercidin
183 Lithium acetoacetate 2 F11 1044 Tyrphostin 1
184 histamine 2 G11 1039 Uridine 5'-monophosphate
185 porphobilinogen 2 H11 1040 Warfarin
186 Acetylthiocholine chloride 2 A12 1025
187 N-Vanillylnonanamide 2 B12 1041
192 (±)-Carnitine chloride 2 H12 1046
193 Duroquinone 3 A1 1025
194 Pentyl vinyl carbinol 3 B1 1041
195 Adenine (Vitamin B4) 3 C1 1042
196 Menadione (vitamin k3) 3 D1 1043
197 D-Panthenol 3 E1 1043
198 3,5-Diiodo-L-tyrosine dihydrate 3 F1 1045
199 3-(1-Naphthyl)-D-alanine 3 G1 1039
200 Theophylline 3 H1 1046
201 Alaproclate hydrochloride 3 A2 1033
202 Quercetin dihydrate 3 B2 1071
203 Hydralazine hydrochloride 3 C2 1069
204 Eserine (Physostigmine) 3 D2 1043
205 Novobiocin sodium salt 3 E2 
206 Didecyldimethylammonium bromide 3 F2 1064
207 S-(-)-Carbidopa 3 G2 1058
208 N-p-Tosyl-L-phenylalanine chloromethyl ketone 3 H2 1046
209 3-Isobutyl-1-methylxanthine 3 A3 1033
210 Lithium potassium acetyl phosphate 3 B3 1058
211 12-Hydroxydodecanoic acid 3 C3 1042
212 D-(+)-Gluconic acid-lactone 3 D3 1043
213 Nalidixic acid 3 E3 1044
214 3-Iodo-L-tyrosine 3 F3 1045
215 Cyclo(His-Pro) 3 G3 1074
216 1-Aminocyclopropanecarboxylic acid 3 H3 1056
217 3-Indoleacetic acid 3 A4 1033
218 Dansylcadaverine 3 B4 1055
219 2-Fluoroaniline 3 C4 1055
220 Tubercidin 3 D4 1057
221 D(+)-Galactosamine hydrochloride 3 E4 1070
222 1-Methylimidazole 3 F4 1055
224 Phenylpyruvic acid 3 H4 1056
225 Pentaethylene glycol 3 A5 1056
226 N-Propyl-1,3-propanediamine 3 B5 1069
227 2',3'-Dideoxyadenosine 3 C5 1068
228 Pyridoxal 5'-phosphate 3 D5 1069
229 2-Aminothiazol 3 E5 1067
230 2-Hydroxyethyl disulfide 3 F5 1067
231 Androsterone 3 G5 1067
233 Ureidosuccinic acid 3 A6 1066
234 Dimethyl 2-oxoglutarate 3 B6 1067
235 D-Citrulline 3 C6 
236 2-Cyclohexen-1-one 3 D6 1065
237 Pseudothiohydantoin 3 E6 1066
238 Cyclohexylamine 3 F6 1065
239 Picrotin 3 G6 1065
240 (-)-Bilobalide Ginkgo biloba leaves 3 H6 1066
242 Tyramine 3 B7 1056
243 Triethylenetetramine Trientine 3 C7 1058
244 2-Aminofluorene 3 D7 1064
245 Ethidium bromide 3 E7 1054
290 2-Amino-4-methylthiazole 3 B9 1071
291 2-Amino-5-methylthiazole 3 C9 1059
292 2-Amino-4-methylphenol, 2-Amino-p-cresol 3 D9 1060
293 2-Aminophenol 3 E9 1061
294 2'-Deoxyadenosine 5'-monophosphate 3 F9 1063
295 2-Aminopyridine 3 G9 1060
297 2-Ethylimidazole 3 A10 1061
298 3,4-Dimethylphenol 3 B10 1059
299 DL-p-Chlorophenylalanine 2 E4 1029
300 2-Methylimidazole 3 C10 1062
301 2-Ketoglutaric acid 3 D10 1062
302 3,4-Dimethylaniline 3 E10 1055
303 Cordycepin 3 F10 1063
304 3-Aminopyridine 3 G10 1058
305 3-Chlorophenol 3 H10 1075
306 Adenosine 5'-monophosphoric acid 3 F7 1054
307 Cytidine 5'-monophosphate 3 G7 1059
308 2-Deoxyguanosine-5-monophosphate 3 H7 1060
309 Inosine 5'-monophosphate disodium salt 3 A8 1060
310 Thymidine 5'-monphosphate 3 B8 1061
311 Uridine 5'-monophosphate 3 C8 1062
312 Kaempferol 3 D8 1061
313 Bisbenzimide H 33258 3 E8 1059
314 Netropsin dihydrochloride hydrate 3 F8 1063
315 Choline phosphate chloride 3 G8 1075
316 Warfarin 1 F4 1053
317 5,5-Diphenylhydantoin 1 D11 1053
318 2'-Deoxyadenosine 3'-monophosphate 3 A9 1064
320 Chlorotetracycline hydrochloride 5 B4 1081
321 Buspirone hydrochloride 2 E12 1047
322 Clenbuterol hydrochloride 2 F12 1102
323 Acridine Orange base 2 G12 1072
324 3-Quinolinecarboxylic acid 3 B2 1071
325 Ciprofloxacin 3 H5 1074
326 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate (Ethacridine) 3 H8 1074
327 Alizarin Yellow R 3 B9 1071
328 Orange II sodium salt 3 H9 1075
330 Aldosterone 3 A11 1071
331 Ampicillin 3 B11 1071
332 Furosemide 3 C11 1072
333 Ibuprofen a-Methyl-4-(isobutyl)phenylacetic acid 2-(4-ISOBUTYLPHENYL)PROPIONIC ACID 3 D11 1072
335 Aquocobalamin 5 C4 1106
337 Digitoxin 3 F11 1073
338 Oxacillin 3 F12 1057
339 Phenol Red 3 G11 1073
340 Bromocresol Green 3 H11 1073
341 Bromophenol Blue 3 A12 1062
343 Naproxen 3 B12 1072
344 Clofibrate 3 C12 1072
345 Sodium salicylate 3 D12 1104
346 6-Amino-3-methylpurine 2 D12 1049
348 (+)-Pseudoephedrine hydrochloride 3 E12 1108
350 N-Acetylneuraminic acid 3 G12 1074
351 Methyl 4-hydroxyphenylacetate 3 H12 1073
352 3,3',5-Triiodothyroacetic acid 4 A1 1076
353 Diaminobiotin 4 B1 1079
354 5-Phenylvaleric acid 4 C1 1082
355 PTH-tryptophan 4 D1 1085
356 6-Phosphogluconic acid trisodium salt D-Gluconate 6-phosphate 4 E1 1087
357 N-(1H-Benzotriazol-1-ylphenylmethyl)benzamide 4 F1 1090
358 7-Deazaguanine 4 G1 1092
359 N-Acetyl-D-galactosamine 4 H1 1111
360 Benzylamine 4 A2 1076
361 Dansylglycin 4 B2 1079
362 Agmatine sulfate salt 4 C2 1082
363 5a-Androstane-3,17-dione 4 D2 1085
364 Resorufin acetate 4 E2 1087
365 Cephalexin hydrate 4 F2 1090
366 trans-4-(Aminomethyl)cyclohexanecarboxylic acid Tranexamic acid 4 G2 1092
367 Androstenedione 4-Androstene-3,17-dione 4 H2 1103
368 Acetazolamide 4 A3 1076
369 Bestatin hydrochloride 4 B3 1079
370 Diminazene aceturate Berenil 4 C3 1082
371 Sodium cacodylate trihydrate 4 D3 1085
372 (±)-Camphor 4 E3 1088
373 Cefoxitin 4 F3 1090
374 Chloramphenicol 4 G3 1093
375 Clindamycin 4 H3 1095
376 Methotrexate hydrate, (+)-Amethopterin 4 A4 1076
377 Amoxicillin 4 B4 1105
378 (-)-Arctigenin 4 C4 1082
380 Oxolinic acid 4 E4 1088
381 Daunorubicin 4 F4 1091
382 5-Azacytidine 4 G4 1110
383 3-Indoleacrylic acid 4 H4 1095
384 Doxorubicin hydrochloride, Adriamycin, Hydroxydaunorubicin 4 A5 1077
386 Podophyllotoxin 4 C5 1083
387 Lumicolchicine 4 D5 1085
389 N,N'-Dicyano-2,5-dimethylbenzoquinone-diimine 4 F5 1109
390 Dipyrone 4 G5 1093
391 Sulindac Sulfide 4 H5 1095
392 Diethylstilbestrol 4 A6 1077
393 H-7 dihydrochloride 4 B6 1080
394 Roscovitine 4 C6 1083
395 Tyrphostin 1 4 D6 1097
396 Tyrphostin 25 4 E6 1088
397 Curcumin 4 F6 1110
398  5-Fluoro-5'-deoxyuridine 4 G6 1093
399 Taxifolin 4 H6 1095
401 Resveratrol 4 B7 1080
402 Silibinin 4 C7 1083
403 Cimetidine 4 D7 1086
404 Cyclophosphamide monohydrate 4 E7 1107
405 1-Octanol 4 F7 1091
408 Tolbutamide 4 A8 1077
410 tert-Butyl carbazate 4 C8 1083
411 AY 9944 4 D8 1086
412 Amantadine hydrochloride 4 E8 1088
413 p-Aminohippuric acid 4 F8 1091
416 Psoralen 4 A9 1077
417 5-Hydroxyindole-3-acetic acid 4 B9 1080
418 4-Hydroxy-3-methoxyphenylglycol sulfate potassium salt 4 C9 1084
419 N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide 4 D9 1086
420 Adrenochrome 4 E9 1089
421 Aflatoxin B1 4 F9 1091
422 DL-4-Hydroxy-3-methoxymandelic acid 4 G9 1094
423 Tamoxifen 4 H9 1096
424 Diclofenac sodium salt 4 A10 1078
425 Benzoic acid 4 B10 1080
426 Ethylenediaminetetraacetic acid, Edathamil 4 C10 1084
427 2-Fluoro-2-deoxy-D-glucose 6-phosphate barium salt 4 D10 1086
428 Astemizole 4 E10 1089
429 Brefeldin A 4 F10 1110
431 1,7-Dimethylxanthine 4 H10 1113
432 Estriol 4 A11 1078
433 Flutamide 4 B11 1081
434 4-Guanidinobutyric acid 4 C11 1097
435 Haloperidol metabolite I 4 D11 1087
436 Homovanillic acid 4 E11 1089
437 3-Hydroxy-DL-kynurenine 4 F11 1092
438 3-Hydroxy-4-methoxyphenethylamine hydrochloride, 4-Methoxytyramine hydrochloride 4 G11 1094
439 4-Hydroxytamoxifen 4 H11 1096
440 Leflunomide 4 A12 1100
442 3-Methoxytyramine hydrochloride 4 D12 1106
443 Minoxidil 4 E12 1108
444 Molsidomine 4 F12 1111
445 Myriocin from Mycelia sterilia 4 G12 1111
448 Dobutamine hydrochloride 5 B1 1105
449 Pentoxifylline 5 C1 1105
450 Amitriptyline hydrochloride 5 D1 1104
452 Bithionol 5 F1 1107
454 Griseofulvin 5 H1 1107
456 Indomethacin 5 A2 1103
457 Kynurenic acid 5 B2 1081
458 Mycophenolic acid 5 C2 1084
459 Nitrendipine 5 D2 1087
460 (±)-Propranolol hydrochloride 5 E2 1089
461 Nifedipine 5 G2 1094
462 N-Acetylprocainamide hydrochloride,Acecainide hydrochloride 5 H2 1096
463 L-Pipecolic acid 5 A3 1113
464 1,3-Dimethyluric acid 5 B3 1081
465 Carisoprodol 5 C3 1084
466 4-Hydroxytamoxifen 5 D3 
467 Cyproheptadine 5 E3 1090
468 (-)-Bicuculline methiodide 5 F3 1092
469 Mecamylamine hydrochloride 5 G3 1094
470 Metergoline 5 H3 1066
471 (±)-Verapamil hydrochloride 5 A4 1078
475 1-Phenyl-1-cyclopropanecarboxylic acid 3 G4 1112
476 2-Pyridineacetic acid hydrochloride 4 B5 1112
477 Ethyl 3-pyridineacetate 4 E5 1113
478 2-Acetamidophenol 4 F6 1110
482 Dimethyl 4-methoxyisophthalate 5 A3 1113
483 5-Aminosalicylic acid, Mesalamine, 5-AS 5 D4 1112
484 2-Nitrophenol 5 E4 
485 Myristic acid 4 B12 1100
486 2,3,5-Triiodobenzoic acid 5 F2 1105
487 2,6-Diisopropylphenol 5 E1 1097
488 Halothane 5 F4 
489 Azidothymidine 5 G4 
490 Acycloguanosine 5 H4 
491 Cefuroxime sodium salt 5 A5 1101
492 5-Fluorocytosine 5 B5 1107
493 Cromolyn sodium salt 5 C5 1104
494 Ebselen 5 D5 1110
495 Methotrexate, (+)-Amethopterin 5 E5 1098
496 Antipyrine 5 F5 1101
497 Atenolol 5 G5 1098
498 Chloramphenicol 1 c7 
499 Cimetidine 5 A6 1101
500 Chlorpropamide 5 B6 1107
501 Hydrochlorothiazide 5 C6 1109
502 Tolazamide 5 D6 
503 Nadolol 5 E6 1098
504 Prednisolone 1,4-Pregnadiene-11ß,17a,21-triol-3,20-dione 1-Dehydrocortisol 1-Dehydrohydrocortisone 5 F6 1099
505 (-)-Scopolamine hydrobromide trihydrate Hyoscine hydrobromide Scopine tropate 5 G6 1100
506 Timolol maleate salt 5 H6 1099
507 (±)-Metoprolol (+)-tartrate salt 5 A7 1109
508 Lidocaine hydrochloride 5 B7 1108
509 Sulfaphenazole 5 C7 1109
510 Acebutolol hydrochloride 5 D7 1111
511 Procaine hydrochloride 5 E7 1098
512 Clonidine hydrochloride 5 F7 1099
513 Ranitidine hydrochloride 5 G7 1099
514 Camptothecin 5 H7 1100
515 Tetracycline 5 A8 1102
517 5-Hydroxyisophthalic acid 4 G8 1093
518 Carbamazepine 4 E10 1103
aOnly the compound shown to bind a protein are listed. The entire list of compounds comprising the functional screening library is listed in the first column
UniProt ID HSA BSA Primase_SA PrgI SAV1430 YtfP PA1324 YkvR YkfF Nuclease Aor Hvu Bam Bli Iba STM1790 DGKA YjbR UFC1
P02768 HSA 0.98 0.98 0.07 0.28 - - - - - - 0.05 0.02 0.04 0.04 0.03 - 0.23 - 0.49
P02769 BSA 0.98 0.98 0.07 0.28 - - - - - - 0.05 0.03 0.04 0.04 0.04 - 0.25 - 0.49
Q5HFJ8 Primase_SA 0.07 0.07 0.98 - - - - - - 0.2 0.15 0.19 0.19 0.17 - 0.24 - 0.15
P41784 PrgI 0.28 0.28 0.99 - - - - - - 0 0 0 0 0 - 0 - 0
Q99U58 SAV1430 - - - - - - - - - - - - - - - - - - -
P0AE50 YtfP - - - - - - - - - - - - - - - - - - -
Q9I420 PA1324 - - - - - - - - - - - - - - - - - - -
O31683 YkvR - - - - - - - - - - - - - - - - - - -
P75677 YkfF - - - - - - - - - - - - - - - - - - -
P00644 Nuclease - - - - - - - - - - - - - - - - - - -
P0C1B3 Aor 0.05 0.05 0.2 0 - - - - - - 0.74 0.64 0.68 0.68 0.67 - - - -
P16098 Hvu 0.02 0.03 0.15 0 - - - - - - 0.64 0.72 0.63 0.63 0.71 - - - -
P00692 Bam 0.04 0.04 0.19 0 - - - - - - 0.68 0.63 0.68 0.68 0.63 - - - -
P06278 Bli 0.04 0.04 0.19 0 - - - - - - 0.68 0.63 0.68 0.68 0.63 - - - -
P10537 Iba 0.03 0.04 0.17 0 - - - - - - 0.67 0.71 0.63 0.63 0.71 0.07 - 0.22
Q8ZP25 STM1790 - - - - - - - - - - - - - - - - - - -
P23743 DGKA 0.23 0.25 0.24 0 - - - - - - 0.14 0.07 0.11 0.11 0.07 - 0.96 - 0.03
P0AF51 YjbR - - - - - - - - - - - - - - - - - - -
Q9Y3C8 UFC1 0.49 0.49 0.15 0 - - - - - - 0.2 0.22 0.07 0.07 0.22 - 0.03 - 0.98
Supplementary Table 2S: Functional similarity scores measured by FunSimMat between all pairs of proteins.
a   
aThe absence of a functional similarity score indicates that at least one of the two proteins lacked GO annotation terms.
Supplementary Tables for “A Correlation between Protein Function and Ligand Binding Profiles” Matthew D. Shortridge, Michael Bokemper, Jennifer C. Copeland, Jamie Stark and Robert Powers*  
Supplementary Table 3S: Pairwise comparison of all ligand binding profiles used in this study (E-values).
a 
HSA BSA Primase_SA PrgI SAV1430 YtfP PA1324 YkvR YkfF Nuclease Aor Hvu Bam Bli Iba STM1790 DGKA YjbR UFC1
HSA 2.32E-68 2.16E-58 5.16E-02 6.48E-02 2.38E-02 1.29E+00 1.19E+00 - - 2.18E-02 6.02E-02 2.43E-03 4.03E-01 2.73E-02 1.88E-02 4.89E-02 4.23E+01 2.22E-02 1.58E-01
BSA 2.16E-58 1.32E-68 1.35E-02 5.98E-02 3.25E-02 7.08E+00 3.17E-03 - - 2.82E-04 5.89E-04 6.43E-01 7.33E-02 3.48E-02 3.59E-02 2.82E-04 3.22E+01 3.05E-02 2.22E-02
Primase_SA 5.16E-02 1.35E-02 2.09E-18 8.18E-03 - - - - - 1.26E-01 1.25E-01 3.30E-02 1.25E-01 4.11E-02 - 6.92E-02 - - 1.08E-02
PrgI 6.48E-02 5.98E-02 8.18E-03 9.58E-10 1.48E-01 - - - - - 1.42E-01 1.48E-01 1.44E-01 1.48E-01 1.48E-01 1.30E-01 - - 1.88E-02
SAV1430 2.38E-02 3.25E-02 - 1.48E-01 3.27E-34 1.03E-02 8.46E-02 - - 6.86E-02 3.77E-02 6.19E-02 8.30E-02 1.02E-01 1.81E-02 6.86E-02 - 2.80E-03 1.03E-01
YtfP 1.29E+00 7.08E+00 - - 1.03E-02 1.75E-19 - 1.32E-02 - - 5.39E-03 - - - - - 1.31E-01 2.32E-02 -
PA1324 5.43E-01 3.17E-03 - - 8.46E-02 - 2.96E-26 - - 1.17E-01 4.21E-02 9.97E-02 5.08E-02 1.02E-01 9.97E-02 3.27E-02 - 7.67E-02 5.47E-03
YkvR 5.10E+00 - - - - 5.59E-04 - 3.91E-11 - - - - - - - - - 1.46E-01 1.43E-01
YkfF 1.47E-01 4.27E+00 - - 5.35E-02 5.59E-04 - 3.12E-03 3.91E-11 - - 5.08E-02 - - - - - - -
Nuclease 2.18E-02 2.82E-04 1.26E-01 - 6.86E-02 - 1.17E-01 - - 1.93E-24 8.32E-05 1.56E-02 2.84E-08 6.46E-02 2.25E-03 4.96E-02 7.66E-02 1.97E-04 1.13E-01
Aor 6.02E-02 5.89E-04 1.25E-01 1.42E-01 3.77E-02 5.39E-03 4.21E-02 - - 8.32E-05 2.83E-38 2.98E-08 6.38E-19 1.19E-15 2.98E-08 2.99E-02 2.12E-02 7.34E-03 7.09E-03
Hvu 2.43E-03 6.43E-01 3.30E-02 1.48E-01 6.19E-02 - 9.97E-02 - - 1.56E-02 2.36E-09 6.69E-32 1.17E-10 3.86E-06 2.45E-09 1.56E-02 1.24E-01 8.69E-03 2.85E-03
Bam 4.03E-01 7.33E-02 1.25E-01 1.44E-01 8.30E-02 - 5.08E-02 - - 2.84E-08 3.18E-20 1.66E-09 1.25E-37 1.42E-14 7.56E-12 2.76E-02 1.95E-02 7.63E-02 9.51E-02
Bli 2.73E-02 3.48E-02 4.11E-02 1.48E-01 1.02E-01 - 1.02E-01 - - 6.46E-02 1.19E-15 3.86E-06 2.62E-13 9.48E-33 2.43E-08 1.40E-02 5.19E-02 1.13E+00 7.08E-02
Iba 1.88E-02 3.59E-02 - 1.48E-01 1.81E-02 - 9.97E-02 - - 2.25E-03 2.98E-08 2.45E-09 7.56E-12 2.43E-08 1.73E-33 6.86E-02 - 1.40E-02 1.09E-01
STM1790 4.89E-02 2.82E-04 6.92E-02 1.30E-01 6.86E-02 - 3.27E-02 - - 4.96E-02 2.99E-02 1.56E-02 2.76E-02 1.40E-02 6.86E-02 1.93E-24 - 1.40E-02 3.34E-04
DGKA 4.23E+01 3.22E+01 - - - 1.31E-01 - - - 7.66E-02 2.12E-02 1.24E-01 1.95E-02 5.19E-02 - - 1.55E-22 6.50E-04 1.03E-01
YjbR 2.22E-02 3.05E-02 - - 2.80E-03 2.32E-02 7.67E-02 - - 1.97E-04 7.34E-03 8.69E-03 7.63E-02 1.71E-02 1.40E-02 1.40E-02 6.50E-04 3.79E-31 1.66E-02
UFC1 1.58E-01 2.22E-02 1.08E-02 1.88E-02 1.03E-01 - 5.47E-03 - - 1.13E-01 7.09E-03 2.85E-03 9.51E-02 7.08E-02 1.09E-01 3.34E-04 1.03E-01 1.66E-02 2.33E-25
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aThe absence of an E-value indicates the two proteins did not have any binding ligands in common.
